UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT

European journal of nuclear medicine and molecular imaging, 2010-01, Vol.37 (1), p.67-77

2010

Volltextzugriff (PDF)

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

European journal of nuclear medicine and molecular imaging, 2015-01, Vol.42 (1), p.5-19

2015

Volltextzugriff (PDF)

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

The Journal of infectious diseases, 2016-07, Vol.214 (1), p.16-22

2016

Volltextzugriff (PDF)

First-in-Humans Study of the SSTR Antagonist 177 Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Journal of Nuclear Medicine, 2021-11, Vol.62 (11), p.1571-1581

2021

Volltextzugriff (PDF)

Thoracic duct embolization and disruption for treatment of chylous effusions: experience with 105 patients

Journal of vascular and interventional radiology, 2014-09, Vol.25 (9), p.1398-1404

2014

Volltextzugriff (PDF)

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT

European journal of nuclear medicine and molecular imaging, 2016-05, Vol.43 (5), p.964-973

2016

Volltextzugriff (PDF)

Prognostic Value of 18 F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2020-11, Vol.61 (11), p.1560-1569

2020

Volltextzugriff (PDF)

Uterine artery embolization in the treatment of postpartum uterine hemorrhage

Journal of vascular and interventional radiology, 2011-02, Vol.22 (2), p.169-176

2011

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors

Clinical nuclear medicine, 2023-03, Vol.48 (3), p.221-227

2023

Volltextzugriff (PDF)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin

Scientific reports, 2019-03, Vol.9 (1), p.4339, Article 4339

2019

Volltextzugriff (PDF)

Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Journal of Nuclear Medicine, 2019-09, Vol.60 (9), p.1259-1265

2019

Volltextzugriff (PDF)

Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

European journal of nuclear medicine and molecular imaging, 2015-07, Vol.42 (8), p.1223-1230

2015

Volltextzugriff (PDF)

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor

World journal of gastroenterology : WJG, 2009-12, Vol.15 (46), p.5867-5870

2009

Volltextzugriff (PDF)

177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma

Clinical nuclear medicine, 2020-05, Vol.45 (5), p.e232-e235

2020

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy

Clinical nuclear medicine, 2020-03, Vol.45 (3), p.241-243

2020

Volltextzugriff (PDF)

Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist

Clinical nuclear medicine, 2020-03, Vol.45 (3), p.e165-e168

2020

Volltextzugriff (PDF)

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177 Lu-FAP-2286: First-in-Humans Results

Journal of Nuclear Medicine, 2022-03, Vol.63 (3), p.415-423

2022

Volltextzugriff (PDF)

Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm

Clinical nuclear medicine, 2018-09, Vol.43 (9), p.676-678

2018

Volltextzugriff (PDF)

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms

Oncotarget, 2015-02, Vol.6 (5), p.3346-3358

2015

Volltextzugriff (PDF)

Impact of exclusion criteria on patient selection for endovascular abdominal aortic aneurysm repair

Journal of vascular surgery, 2001-12, Vol.34 (6), p.1050-1054

2001

Volltextzugriff (PDF)

Pregnancy and Delivery After PRRT Without Sequelae

Clinical nuclear medicine, 2018-11, Vol.43 (11), p.842-845

2018

Volltextzugriff (PDF)

Safety and utility of transjugular liver biopsy in hematopoietic stem cell transplant recipients

Journal of vascular and interventional radiology, 2013-01, Vol.24 (1), p.85-89

2013

Volltextzugriff (PDF)

Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors

Recent results in cancer research, 2013, Vol.194, p.379

2013

Volltextzugriff (PDF)

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC

Recent results in cancer research, 2013, Vol.194, p.519

2013

Volltextzugriff (PDF)

EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies

Future oncology (London, England), 2012-10, Vol.8 (10), p.1349-1359

2012

Volltextzugriff (PDF)

1 – 25 von 262

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(256)
Mit Volltextzugriff
(158)

Publikationsform

Artikel
(262)

Sprache

Englisch
(262)

Erscheinungsjahr

n.n

Thema

Humans
(249)
Science & Technology
(202)
Life Sciences & Biomedicine
(193)
Male
(188)
Middle Aged
(137)
Adult
(125)
Aged
(107)
Biological And Medical Sciences
(71)
Medical Sciences
(66)
Aged, 80 And Over
(47)
Adolescent
(45)
Radiology, Nuclear Medicine & Medical Imaging
(45)
Young Adult
(35)
Child
(32)
Prospective Studies
(32)
Treatment Outcome
(31)
Follow-Up Studies
(30)
Surgery
(29)
Animals
(28)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

First-in-Humans Study of the SSTR Antagonist 177 Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Thoracic duct embolization and disruption for treatment of chylous effusions: experience with 105 patients

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT

Prognostic Value of 18 F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Uterine artery embolization in the treatment of postpartum uterine hemorrhage

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin

Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor

177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma

Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy

Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177 Lu-FAP-2286: First-in-Humans Results

Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms

Impact of exclusion criteria on patient selection for endovascular abdominal aortic aneurysm repair

Pregnancy and Delivery After PRRT Without Sequelae

Safety and utility of transjugular liver biopsy in hematopoietic stem cell transplant recipients

Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC

EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies

Aktive Filter

Suchergebnisse filtern